Key result
Raw Moutan Cortex extract alters pharmacokinetics in rats by inhibiting inflammation and regulating coagulation.
Why the study?
Raw Moutan Cortex is used for cooling blood and promoting blood circulation, but its therapeutic mechanism remains undefined.
Does Raw Moutan Cortex extract alter pharmacokinetic parameters and regulate specific targets in blood-heat and blood stasis syndrome models?
Does Raw Moutan Cortex extract alter pharmacokinetic parameters and regulate specific targets in blood-heat and blood stasis syndrome models?
Raw Moutan Cortex extract alters pharmacokinetics in blood-heat and blood stasis syndrome models and may exert therapeutic effects by inhibiting inflammatory pathways and regulating coagulation cascades.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in blood stasis syndromes; hypothesis-generating for inflammatory and coagulation targets in animal models.
BACKGROUND: Raw Moutan Cortex (RMC) has been used in China and other Asian countries for thousands of years. Its medical application is the treatment of cooling blood and promoting blood circulation. However, its therapeutic mechanism is still undefined. METHODS: In this study, the pharmacokinetics strategy that integrated network analysis was employed to explore the mechanism of RMC in blood-heat and blood stasis syndrome (BHS) model rats. Firstly, Ultra-High performance Liquid Chromatography coupled with Diode Array Detector (UHPLC-DAD) method was developed to determine nine absorbed compounds in rat serum in BHS and normal rats after oral administration of RMC extract respectively. Then the pharmacology network was established based on the relationship between nine compounds absorbed into the blood and BHS targets. Finally, the predicted hub targets were validated experimentally in human umbilical vein endothelial cells (HUVECs). RESULTS: Pharmacokinetic study showed that the pharmacokinetic parameters of nine absorbed compounds had significant differences between BHS and normal groups (p < 0.05). Network analysis showed that 8 target genes, namely, F2, F10, F7, PLAU, MAPK14, MAPK10, AKT1, and NOS3 may be the primary targets regulated by RMC for the treatment of BHS. Among them, targets (F2, F10, F7 and MAPK14, MAPK10, AKT) and 4 active ingredients (paeonol, paeoniflorin, quercetin and oxypaeoniflorin) were selected for evaluating the reliability in vitro experiments, which revealed that the mechanism of RMC against BHS syndrome may inhibit inflammatory pathways and regulate coagulation cascades pathway for cooling and promoting blood circulation. CONCLUSION: The proposed pharmacokinetics study integrated network analysis strategy provides a combination method to explore the therapeutic mechanism of RMC on BHS.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2022) studied Blood-heat and blood stasis syndrome (BHS) (n=24). Raw Moutan Cortex (RMC) extract vs. Normal rats and untreated BHS model rats was evaluated on Pharmacokinetic parameters (AUC, Cmax, CL/F) of nine absorbed compounds (p=<0.05). Raw Moutan Cortex extract significantly altered the pharmacokinetics of nine absorbed compounds in BHS rats and exerted its therapeutic effects by inhibiting inflammatory pathways and regulating coagulation cascades.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: